Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Inclusion Criteria:

Phase 1 Inclusion

• Participant at least 18 years of age with histologically confirmed CLL/SLL or B-cell
non-Hodgkin lymphoma (diffuse large B-cell lymphoma [DLBCL], FL, mantle cell lymphoma
[MCL], marginal zone lymphoma [MZL], lymphoplasmacytic lymphoma).

Phase 2a Inclusion

   - Histological evidence: FL Grade 1-3A, with relapsed or refractory disease; aggressive
   NHL (aNHL), defined as DLBCL, FL Grade 3B, MCL, and transformed NHL with relapsed
   disease; CLL/SLL, peripheral T-cell lymphoma (PTCL), or cutaneous T-cell lymphoma
   (CTCL) (with mycosis fungoides [MF]/Sézary Syndrome [SS]) with relapsed or refractory
   disease

   - Received B-cell receptor (BCR) and/or BCL2 inhibitors and were intolerant or had
   relapsed/refractory disease afterwards

   - Prior treatment for lymphoid malignancy for progressive /refractory disease

   - ≥1 prior regimen (minimum 2 cycles) with antibody conjugate/cytotoxic chemotherapy.

   - Measurable disease defined as: ≥1 lesion that measures ≥1.5 centimeter (cm) single
   dimension via computed tomography (CT), CT/positive-emission tomography (PET) with
   nodal or mass lesions; quantifiable circulating tumor cells; and for CTCL: Modified
   Severity Weighted Assessment Tool (mSWAT) >0

   - Ability to provide diagnostic reports

General Inclusion

   - Eastern Cooperative Oncology Group (ECOG) Score of 0 or 1

   - Hematologic absolute neutrophil count (ANC) >1000/microliter (uL) and platelet
   >75,000/uL

   - Creatinine levels as specified by Investigator

   - Bilirubin <2.0 mg/deciliter [dL] (if Gilberts then <2.5 mg/dL) and aspartate
   aminotransferase (AST)/alanine aminotransferase (ALT) <2.5*ULN

Exclusion Criteria:

   - Richter's syndrome, Burkitt's lymphoma, or Burkitt-like Lymphoma (transformed DLBCL
   from follicular NHL are eligible)

   - Prior transplant with stem cell infusion within 90 days of Day 1 or active
   graft-versus-host treatment within 8 weeks of Day 1

   - Prior therapy with Spleen Tyrosine Kinase (SYK) inhibitors

   - Chronic treatment with strong CYP3A4 inhibitor/inducer

   - Known lymphomatous involvement of the central nervous system (CNS)

   - Persistent, unresolved National Cancer Institute (NCI) Common Toxicity Criteria for
   Adverse Events (CTCAE) version 5.0 ≥Grade 2, previous drug-related toxicity (except
   alopecia, erectile impotence, hot flashes, libido, neuropathy).

   - Prior monoclonal antibody (including alemtuzumab), radioimmunoconjugate, antibody drug
   conjugate, phototherapy, radiotherapy, chemotherapy, immunotherapy, immunosuppressive
   therapy, or any test agent within 3 weeks of Day 1

   - For CTCL: (total skin electron beam therapy [TSEBT]) within 12 weeks, or initiation of
   topical steroid, nitrogen mustard, or topical retinoid within 2 weeks. Stable topical
   regimen for ≥4 weeks prior to Day 1 allowed.

   - Known carrier or infection for human immunodeficiency virus (HIV)/hepatitis B or C. If
   hepatitis C virus (HCV) antibody (ab)+, must be polymerase chain reaction (PCR)- to be
   eligible. If hepatitis B virus (HBV) ab+, must be hepatitis B surface antigen (HBsAg)-
   or undetectable HBV deoxyribonucleic acid (DNA) to be eligible.

   - Active infection requiring systemic treatment,

   - Significant gastrointestinal (GI) disease, previous major gastric/bowel surgery,
   difficulty swallowing, or malabsorption syndrome

   - Major surgery within 4 weeks

   - Previous malignancies within 2 years unless relapse risk is small (<5%).

   - Current use of systemic steroids >20 mg QD prednisone (or equivalent)

   - Breastfeeding or pregnant (intention to become) females or participation in other
   clinical trials